COMMENT

Telemedicine for treating mental health and substance use disorders: reflections since the pandemic

Neuropsychopharmacology (2021) 46:1068–1070; https://doi.org/10.1038/s41386-021-00960-4

INTRODUCTION

Since the United States COVID-19 pandemic emergency began, telemedicine use has accelerated [1]. Prior to the pandemic, mental health and/or substance use disorder (MH/SUD) care delivered by telemedicine had been increasing but infrequently used—in fewer than 1% of visits [2, 3]. In contrast, in early October 2020, 41% of MH/SUD visits were conducted via telemedicine [4]. The rapid increase in telemedicine during the pandemic was enabled by sweeping temporary changes in federal and state regulations and health plan reimbursement policies that reduced longstanding barriers. These changes included federal relaxation of HIPAA compliance for telemedicine, removal of the requirement for an initial in-person appointment to prescribe buprenorphine (prohibited under the Ryan Haight Act), Medicare coverage for audio-only telephone visits, and an expanded list of services and types of providers who could deliver telemedicine. Other changes included expanding Medicaid telemedicine coverage policies, requiring commercial insurance parity for in-person versus telemedicine visits, and states allowing out-of-state providers to deliver care [1, 5–7]. Additionally, some commercial insurers voluntarily expanded telemedicine coverage. While the transition to virtual care occurred quickly [8, 9], it is important to take stock of these recent advances as well as continuing challenges. In this Commentary, we briefly describe our transition to telemedicine at McLean Hospital and elaborate on the national health policy and public health context that should inform our thinking on the role of telemedicine in MH/SUD care post-pandemic.

McLean is a psychiatric hospital near Boston, Massachusetts that is part of the Mass General Brigham health system. McLean provides inpatient, residential, partial hospital, and outpatient care for individuals with mental health and substance use disorders; in fiscal year 2019 there were over 45,000 outpatient visits. On March 16, 2020, several days after the governor of Massachusetts declared a state public health emergency, McLean discontinued in-person care for outpatients; the transition to telemedicine video services, which previously had not been used at McLean, occurred within 2 weeks. Outpatient encounters initially decreased during the March transition but by April 2020 rebounded to a similar volume as pre-pandemic (Fig. 1). Video visits predominated and the proportion of phone visits decreased over time.

HEALTH POLICY AND PUBLIC HEALTH CONSIDERATIONS FOR THE USE OF TELEMEDICINE POST-PANDEMIC

Similar to our experience, recent research also finds that nationally telemedicine is playing an important role in preserving MH/SUD care during the pandemic; despite that, there have been some disruptions observed in MH/SUD care [4, 8, 10, 11].

While more research is needed to clarify the patient and systems factors associated with more versus less successful transitions to telemedicine, findings of some care disruption despite rapid telemedicine deployment in MH/SUD care are an important observation. This is because an often stated policy goal of telemedicine is to improve access to care, particularly for patients who lack geographic access to clinicians qualified to treat their illness—for example, rural patients [12, 13]. Furthermore, MH/SUDs are considered to be particularly amenable to care via telemedicine, relative to other health care conditions; for example, earlier research on the diffusion of telemedicine in Medicare found that nearly 80% of telemedicine visits were for mental health conditions [14]. However, there are some patients for whom the use of telemedicine, particularly video visits, poses significant barriers. The "digital divide" affects many patients who are in groups that are already underserved—such as racial or ethnic minorities, those in poverty, and the elderly [15–17]. Recent evidence suggests disparities in receiving MH/SUD care during the pandemic for individuals from these groups [8]. Addressing the digital divide will require a range of solutions to address deficits in community broadband availability, patient access to affordable devices and adequate privacy, assisting patients with digital literacy, health care providers/organizations employing digital solutions that are user-friendly for patients of varying cognitive and physical capabilities, and clinicians overcoming patient mistrust of technology [18].

Additionally, while many patients find telemedicine an adequate or even preferable alternative for in-person care, not all do [19]. There are some clinical characteristics for which in-person care, or a hybrid of in-person and telemedicine visits, would be better for the patient. For example, patients struggling with isolation may be better served by leaving their home to attend treatment. Furthermore, while meta-analyses describe telemedicine's effectiveness for depressive and anxiety disorders [20, 21], there is less evidence for SUDs [22] or schizophrenia [23]. Also lacking is a systematic understanding of effectiveness of certain aspects of clinical care via telemedicine compared to in-person care, such as elements of the mental status exam (e.g., evaluating eye contact); and the experience of virtual group therapy warrants additional research. These gaps will be important to resolve as we think about the role of telemedicine across varied diagnostic populations, post-pandemic.

Additionally, there are clinician-specific factors hindering access to care via telemedicine. Even in non-rural areas, there are shortages of clinicians with specialty MH/SUD expertise [24], and even fewer who accept insurance [25]. The well-documented shortage of specialty clinicians has been an impetus to finding alternative delivery models, such as collaborative care with primary care and digital health to assist in the treatment of patients with milder conditions [26, 27]. Widespread clinician shortages in many communities may limit the success telemedicine can have in improving geographical access to care. This is particularly relevant for patients who require specialized team-based behavioral health care unavailable in their state, due to complex clinician-specific state licensing and prescribing.
We gratefully acknowledge funding from the NIMH (R01MH112829, ABB) and NIDA (R01DA048533, P30 DA035772, ABB and SFG; and K23DA050780, DES). The authors declare no competing interests.

ACKNOWLEDGEMENTS
We thank Elizabeth Fox for analyzing the electronic health record data to provide the outpatient encounter volumes.

AUTHOR CONTRIBUTIONS
ABB, DES, LEH, and SFG conceptualized the overall framework of the Comment content. ABB drafted the first draft; ABB, DES, LEH, and SFG revised it critically for important intellectual content and provided final approval of the version to be published. ABB is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

ADDITIONAL INFORMATION

REFERENCES
1. Bosworth A, Ruhter J, Samson LW, Shengold S, Taplin C, Tarazi W, et al. Medicare beneficiary use of telehealth visits: early data from the start of the COVID-19 pandemic. Washington, DC: Office of the Assistant Secretary for Planning and Evaluation, Department of Health and Human Services; 2020.
2. Huskamp HA, Busch AB, Souza J, Uscher-Pines L, Rose S, Wilcock A, et al. How is telemedicine being used in opioid and other substance use disorder treatment? Health Aff. 2018;37:1940–7.
3. Patel SY, Huskamp HA, Busch AB, Mehrotra A. Telemental health and US rural-urban differences in specialty mental health use, 2010-2017. Am J Public Health. 2020;110:1308–14.
4. Mehrotra A, Chernew M, Linetsky D, Hatch H, Cutler D, Schneider EC. The impact of the COVID-19 pandemic on outpatient care: visits return to prepandemic levels, but not for all providers and patients. 2020. Commonwealth Fund. https://doi.org/10.26099/41xy-9ms57. Accessed 20 Oct 2020.
5. Telehealth: Delivering Care Safely During COVID-19. US Department of Health and Human Services; 2020. https://www.hhs.gov/coronavirus/telehealth/index.html. Accessed 10 Dec 2020.
6. Weigel G, Ramaswamy A, Sobel L, Salganickoff A, Cubanski J, Freed M. Opportunities and barriers for telemedicine in the U.S. during the COVID-19 emergency and beyond. Kaiser Family Foundation; 2020. https://www.kff.org/womens-
10. Uscher-Pines L, Sousa J, Raja P, Mehratra A, Barnett M, Huskamp HA. Suddenly becoming a "Virtual Doctor": experiences of psychiatrists transitioning to telemedicine during the COVID-19 pandemic. Psychiatr Serv. 2020;71:1143–50.
11. Huskamp HA, Busch AB, Uscher-Pines L, Barnett ML, Riedel L, Mehratra A. Treatment of opioid use disorder among commercially insured patients in the context of the COVID-19 pandemic. JAMA. 2020;324:2440–2.
12. Office of National Drug Control Policy. National Drug Control Strategy: National Treatment Plan for Substance Use Disorder 2020. Washington, DC: Executive Office of the President of the United States; 2020. https://www.ojp.gov/sites/default/files/2020-02/NDCS-Treatment-Plan.pdf. Accessed 13 Dec 2020.
13. Centers for Medicare and Medicaid Services. Information on medicare telehealth. US Department of Health and Human Services; 2018. https://www.cms.gov/About-CMS/Agency-Information/OMH/Downloads/Information-on-Medicare-Telehealth-Report.pdf?utm_source=Telehealth+Enthusiasts&utm_campaign=218d4f1f10-EMAIL_CAMPAIGN_2018_11_26_11_35&utm_medium=email&utm_term=0_ae00-b0e99a-218d4f1f10-353223937. Accessed 10 Oct 2020.
14. Mehratra A, Jena AB, Busch AB, Souza J, Uscher-Pines L, Landon BE. Utilization of telemedicine among rural Medicare beneficiaries. JAMA. 2016;365:2015–6.
15. Anderson M, Kumar M. Digital divide persists even as lower-income Americans make gains in tech adoption. Pew Research Center; 2019. https://www.pewresearch.org/fact-tank/2019/05/07/digital-divide-persists-even-as-lower-income-americans-make-gains-in-tech-adoption/. Accessed 24 July 2020.
16. Anderson M, Perrin A. Disabled Americans are less likely to use technology. Pew Research Center; 2017. https://www.pewresearch.org/fact-tank/2017/04/07/disabled-americans-are-less-likely-to-use-technology/. Accessed 20 July 2020.
17. Perrin A, Turner E. Smartphones help Blacks, Hispanics bridge some—but not all—digital gaps with Whites. Pew Research Center; 2019 https://pewrsr.ch/2Z1PKPf. Accessed 20 Aug 2020.
18. Ramsetty A, Adams C. Impact of the digital divide in the age of COVID-19. J Am Med Inform Assoc. 2020;27:1147–8.
19. Cowan KE, McKeen AJ, Gentry MT, Hilty DM. Barriers to use of telepsychiatry: clinicians as gatekeepers. Mayo Clin Proc. 2019;94:2510–23.
20. Drago A, Winding TN, Antypa N. Teleconferencing in psychiatry, a meta-analysis of assessment and treatment. Eur Psychiatry. 2016;36:29–37.
21. Hubley S, Lynch SB, Schneck C, Thomas M, Shore J. Review of key telepsychiatry outcomes. World J Psychiatry. 2016;6:269–82.
22. Lin LA, Casteel D, Shigekawa E, Weyrich MS, Roby DH, McMenamin SB. Telemedicine-delivered treatment interventions for substance use disorders: a systematic review. J Subst Abus Treat. 2019;101:38–49.
23. Santesteban-Echarri O, Piskulic D, Nyman RK, Addington J. Telehealth interventions for schizophrenia-spectrum disorders and clinical high-risk for psychosis individuals: a scoping review. J Telemed Telecare. 2020;26:14–20.
24. Health Resources and Services Administration/National Center for Health Workforce Analysis; Substance Abuse and Mental Health Services Administration/Office of Policy, Planning, and Innovation. National Projections of Supply and Demand for Behavioral Health Practitioners: 2013-2025. Rockville, Maryland. 2015.
25. Bishop TF, Press MJ, Keyhani S, Pincus HA. Acceptance of insurance by psychiatrists and the implications for access to mental health care. JAMA Psychiatry. 2014;71:181.
26. Naslund JA, Shidhaye R, Patel V. Digital technology for building capacity of nonspecialist health workers for task sharing and scaling up mental health care globally. Harv Rev Psychiatry. 2019;27:181–92.
27. Unützer J, Carlo AD, Collins PY. Leveraging collaborative care to improve access to mental health care on a global scale. World Psychiatry. 2020;19:36–37.
28. Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2019 National Survey on Drug Use and Health. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2020.
29. National Center for Quality Assurance. Follow-up after hospitalization for mental illness. https://www.nccpa.org/hedis/measures/follow-up-after-hospitalization-for-mental-illness/. Accessed 8 Oct 2020.